Enhancement by lithium of cAMP-induced CRE/CREB-directed gene transcription conferred by TORC on the CREB basic leucine zipper domain.
The molecular mechanism of the action of lithium salts in the treatment of bipolar disorder is not well understood. As their therapeutic action requires chronic treatment, adaptive neuronal processes are suggested to be involved. The molecular basis of this are changes in gene expression regulated by transcription factors such as CREB (cAMP-response-element-binding protein). CREB contains a transactivation domain, in which Ser119 is phosphorylated upon activation, and a bZip (basic leucine zipper domain). The bZip is involved in CREB dimerization and DNA-binding, but also contributes to CREB transactivation by recruiting the coactivator TORC (transducer of regulated CREB). In the present study, the effect of lithium on CRE (cAMP response element)/CREB-directed gene transcription was investigated. Electrically excitable cells were transfected with CRE/CREB-driven luciferase reporter genes. LiCl (6 mM or higher) induced an up to 4.7-fold increase in 8-bromo-cAMP-stimulated CRE/CREB-directed transcription. This increase was not due to enhanced Ser119 phosphorylation or DNA-binding of CREB. Also, the known targets inositol monophosphatase and GSK3beta (glycogen-synthase-kinase 3beta) were not involved as specific GSK3beta inhibitors and inositol replenishment did not mimic and abolish respectively the effect of lithium. However, lithium no longer enhanced CREB activity when the CREB-bZip was deleted or the TORC-binding site inside the CREB-bZip was specifically mutated (CREB-R300A). Otherwise, TORC overexpression conferred lithium responsiveness on CREB-bZip or the CRE-containing truncated rat somatostatin promoter. This indicates that lithium enhances cAMP-induced CRE/CREB-directed transcription, conferred by TORC on the CREB-bZip. We thus support the hypothesis that lithium salts modulate CRE/CREB-dependent gene transcription and suggest the CREB coactivator TORC as a new molecular target of lithium.
Böer
Ulrike
U
Department of Molecular Pharmacology, University of Göttingen, Robert-Koch-Str. 40, D-37099 Göttingen, Germany. uboeer1@gwdg.de
Eglins
Julia
J
Krause
Doris
D
Schnell
Susanne
S
Schöfl
Christof
C
Knepel
Willhart
W
D000818:Animals; D002460:Cell Line; D006224:Cricetinae; D000242:Cyclic AMP / Q000494:pharmacology; D017362:Cyclic AMP Response Element-Binding Protein / Q000235:genetics / Q000378:metabolism*; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D016350:Leucine Zippers; D008094:Lithium / Q000494:pharmacology*; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D010766:Phosphorylation; D010768:Phosphoserine / Q000378:metabolism; D020218:Response Elements; D014158:Transcription, Genetic / Q000187:drug effects* / Q000235:genetics*
D017362:Cyclic AMP Response Element-Binding Protein; D010768:Phosphoserine; D008094:Lithium; D000242:Cyclic AMP; D000071679:Glycogen Synthase Kinase 3 beta; C000605508:Gsk3b protein, rat; D038362:Glycogen Synthase Kinase 3; D010744:Phosphoric Monoester Hydrolases; C021822:myo-inositol-1 (or 4)-monophosphatase
Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609
11483993
Int J Neuropsychopharmacol. 2007 Aug;10(4):491-6
16923323
J Neurochem. 2001 Sep;78(6):1219-32
11579131
Am J Addict. 2001 Summer;10(3):201-17
11579619
Endocrinology. 2002 Feb;143(2):674-82
11796524
Neuron. 2002 Mar 28;34(1):13-25
11931738
Mol Psychiatry. 2002;7 Suppl 1:S35-45
11986994
Nature. 2002 May 16;417(6886):292-5
12015604
Neuroscience. 2003;116(2):425-35
12559097
J Neurosci. 2003 Aug 13;23(19):7311-6
12917364
Mol Cell. 2003 Aug;12(2):413-23
14536081
Arch Gen Psychiatry. 2003 Dec;60(12):1201-8
14662552
J Neurochem. 2004 Apr;89(2):324-36
15056276
J Biol Chem. 2004 Jun 11;279(24):25234-40
15060069
Cell. 2004 Oct 1;119(1):61-74
15454081
Mol Interv. 2004 Oct;4(5):259-72
15471909
J Biol Chem. 1985 Mar 25;260(6):3440-50
3838314
Neuropharmacology. 1989 Mar;28(3):307-11
2542834
Nucleic Acids Res. 1989 Aug 11;17(15):6419
2771659
J Biol Chem. 1990 May 25;265(15):8725-35
2160464
J Biol Chem. 1993 Nov 5;268(31):23111-5
7693684
Aust N Z J Psychiatry. 1999 Oct;33(5):615-8 and 4 pages following
10544983
Annu Rev Biochem. 1999;68:821-61
10872467
J Biol Chem. 1994 Oct 28;269(43):27036-44
7929445
J Biol Chem. 1994 Dec 23;269(51):32187-93
7798217
J Biol Chem. 1995 Apr 14;270(15):8860-6
7536740
Mol Pharmacol. 1995 Jun;47(6):1112-8
7603449
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8455-9
8710892
Naunyn Schmiedebergs Arch Pharmacol. 1997 Oct;356(4):433-40
9349628
Annu Rev Neurosci. 1998;21:127-48
9530494
Ann N Y Acad Sci. 1997 Dec 29;836:339-51
9616808
Neuron. 1999 Jan;22(1):63-72
10027290
Neuroscience. 1999;91(2):771-6
10366032
Cell. 2004 Dec 29;119(7):1041-54
15620361
Br J Pharmacol. 2005 Apr;144(7):982-93
15711594
Diabetologia. 2006 Feb;49(2):332-42
16369771
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4700-5
17360587
Brain Res Bull. 2001 Jul 15;55(5):625-9
11576759